Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Kontigo Care AB is a healthcare technology company focused on the development and provision of digital health solutions, particularly in the field of addiction treatment and prevention. Its primary product, Previct, is a real-time platform that utilizes mobile health technology to monitor and support patients with addiction issues. By leveraging advanced analytics and machine learning, Kontigo Care aims to provide personalized feedback and data-driven insights that can help healthcare providers better assist their patients. This digital engagement helps enhance patient adherence to treatment plans and improve overall outcomes. Kontigo Care operates within the healthcare and technology sectors, increasingly impacting how behavioral health is managed. The company's innovative approach aligns with global movements towards digital health transformation, making it a significant player in the realm of e-health solutions. As the demand for accessible healthcare technology solutions continues to rise, Kontigo Care's contributions are particularly noteworthy in improving public health responses to addiction challenges worldwide.
kr 0.09
kr 0.00 (-0.92%)
Live · 08:39 PM · Twelve Data
The business is unprofitable at the operating level (-7.27% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 3.7% YoY. Margins deteriorated 10.2pp alongside, both lines moving the wrong way.
ROIC dropped from 1.89% to -3.14%, capital efficiency is deteriorating. Negative free cash flow of -kr 3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 29M
▼ -3.7% YoY
Net Income (TTM)
-kr 1M
▼ -367.6% YoY
Op. Margin
-4.47%
▼ -10.2pp YoY
ROIC
-3.14%
▼ -5.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 1M
▲ +46.8% YoY
Op. Cash Flow (TTM)
-kr 103K
▼ -213.4% YoY
Net Debt
-kr 15M
Net Cash Position
Cash & Equiv.
kr 15M
3Y CAGR: +0.8%
Continue Research
Kontigo Care AB (KONT.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Kontigo Care AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Kontigo Care AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -4.5% operating margin and a -3.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh KONT.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.